Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement and Estimates

More financial data

Real-time Boerse Muenchen Other stock markets 07:44:13 25/09/2025 BST			5-day change	1st Jan Change
0.0985 ^EUR	-0.51%		-.--%	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today

Market Cap	6.15M 7.1M 5.74M 5.25M 9.89M 677M 10.05M 67.36M 26.43M 339M 26.66M 26.08M 1.13B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 68.44M 55.38M 50.61M 95.37M 6.53B 96.87M 649M 255M 3.27B 257M 251M 10.88B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
01/10/25	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

CARMAT Share Price Boerse Muenchen

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Chart: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile

Income Statement and Estimates

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	31/08/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	11/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	31/03/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	01/01/2017
Michael Mack BRD	Director/Board Member	79	19/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-0.51%	-.--%	-	-	7.08M
STRYKER CORPORATION	+0.48%	+3.12%	-8.03%	+22.80%	133B
SMITH & NEPHEW PLC	+0.61%	-1.34%	-17.57%	-1.12%	12.57B
GLAUKOS CORPORATION	-0.18%	+6.30%	+108.32%	+143.69%	10.7B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.30%	-0.35%	-42.48%	-67.21%	4.72B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.79%	+3.51%	-24.77%	+37.61%	2.68B
INSPIRE MEDICAL SYSTEMS, INC.	+0.55%	-7.13%	-25.19%	-75.47%	1.73B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.98%	+1.30%	-14.30%	-12.41%	1.7B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.69%	-2.02%	-33.31%	-31.58%	1.67B
Average	+0.25%	+202.53%	-7.17%	+2.04%	21.05B
Weighted average by Cap.	+0.51%	+360.97%	-3.07%	+24.50%

	2023	2024
Net sales	3.84M 4.43M 3.59M 3.28M 6.18M 423M 6.27M 42.06M 16.5M 211M 16.64M 16.28M 704M	7.34M 8.48M 6.86M 6.27M 11.82M 809M 12.01M 80.5M 31.59M 405M 31.85M 31.16M 1.35B
Net income	-53.87M -62.23M -50.35M -46.02M -86.72M -5.93B -88.07M -590M -232M -2.97B -234M -229M -9.89B	-51.4M -59.37M -48.04M -43.91M -82.74M -5.66B -84.03M -563M -221M -2.83B -223M -218M -9.43B
Net Debt	49.64M 57.34M 46.39M 42.4M 79.9M 5.47B 81.15M 544M 213M 2.74B 215M 211M 9.11B	53.1M 61.34M 49.63M 45.36M 85.48M 5.85B 86.82M 582M 228M 2.93B 230M 225M 9.75B